May 29, 2013, 07.50 PM | Source: CNBC-TV18
Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
Ashu Madan (more)
COO, Religare Capital | Capital Expertise: Equity - Technical ,Equity - Fundamental
“In short-term one might get 10-15 percent return soon. So in any case if somebody can hold it for longer it would be better, but the current price at which it is hovering around is a good price to buy,” Madan said.
Karvy is bullish on Dishman Pharma has recommended
The company had reported a net profit of Rs 40.02
The company's subsidiary Carbogen Amcis AG, Switze
Dishman Pharmaceuticals' subsidiary Carbogen Amcis